The cardiovascular software developer has built modelling programs that could help doctors decide whether patients are fit for surgery.
Feops, a Belgium-based cardiovascular modelling software spinout from Ghent University, has obtained €6m ($7.1m) in series B funding from a consortium including Flemish government-owned investment firm Participatiemaatschappij Vlaanderen (PMV).
The round was led by private equity firm Valiance Asset Management and also featured venture capital firm Capricorn Venture Partners.
Feops offers 3D cardiovascular modelling that can provide detailed imaging of patients awaiting heart surgery.
The company’s first product, TaviGuide, has already been commercialised, while a suite currently under development, Feops HeartGuide, will seek to widen the scope for implant-based cardiovascular therapy.
The series B cash will be used to rapidly develop Feops HeartGuide and expand the market for transcatheter aortic valve implants, often used for those unsuited to traditional operations.
Both PMV and Capricorn had already backed Feops during a €1.3m series A round in 2015.
Matthieu De Beule, chief executive of Feops, said: “Our first commercial product, TaviGuide, is currently the only CE-marked [that is, approved for sale in the European Economic Area] technology that can predict how an aortic valve implant will interact with the patient-specific anatomy and provide guidance for personalised device size selection and position.
“This series B capital will enable us to scale commercial operations, deliver on our pipeline of simulation tools for structural heart and promptly realise the significant opportunity in the growing transcatheter valve market.”
– This article first appeared on our sister site Global Government Venturing.
